Hemopathy, Horton's Disease, Infectious Disease, Neoplasia, Solid Tumor
Conditions
Brief summary
The aim of this open, controlled, multicentre biomedical research study is to identify new markers specifically associated with Horton's disease. This would make it possible to improve the diagnosis and management of this disease. Participation consists in taking one or several blood samples depending on the group patients/controls.
Interventions
OTHER1 blood sample
OTHER2 to 3 blood samples (at inclusion, at 3 months and at 6 months in cases of relapse)
Sponsors
Centre Hospitalier Universitaire Dijon
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
Yes
Inclusion criteria
Patients * Patients who have provided written informed consent * Patients with national health insurance cover * Age: 50 to 90 years Patients with Horton' s disease : * at the diagnosis, before any treatment * or in remission * or in relapse Patients with an infectious disease : * Bacteriologically or radiologically confirmed * Presenting an inflammatory syndrome defined by : * CRP ≥ 10 mg / L * and Fibrinogen ≥ 4 g / L or ESR ≥ 30 mm at H1 Patients with neoplasia ( solid tumour or hemopathy ) : * At the diagnosis, before treatment by chemotherapy * Presenting an inflammatory syndrome defined by: * CRP ≥ 10 mg / L * and Fibrinogen ≥ 4 g / L or ESR ≥ 30 mm at H1 Controls : These are healthy volunteers recruited among blood donators at Dijon CHU, voluntary hospital personnel ( nurses, doctors and secretaries ), patients at the EPHAD ( Champmaillot centre for geriatric patients ) and patients without infectious, inflammatory, or auto-immune disease ( CRP \< 5mg / L ) or cancer recruited from the investigating departments of Dijon CHU. They will be matched for age and sex. * Age: 18 - 90 years * Patients with national health insurance cover * who have provided written informed consent * Absence of an inflammatory syndrome ( CRP \< 5 mg / L )
Exclusion criteria
: * Any patient who does not meet the inclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measure the ability of Treg to proliferate and to synthesize IL-17 in response to different antigenic stimulations | Up to 6 months |
| Quantification of specific cytokines of the Th17 immune response (IL-17 A and IL-23) in the serum | Up to 6 months |
| Quantification of LTh17 by flow cytometry | Up to 6 months |
| Measurement of the activation level of genes specifically involved in Th17 response using RT-PCR on frozen mRNA | Up to 6 months |
Countries
France
Outcome results
None listed